Managing Hypertension In Heart Failure Patients In A Teaching Hospital In Ghana
|
|
- Gerald Harrell
- 5 years ago
- Views:
Transcription
1 ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Managing Hypertension In Heart Failure Patients In A Teaching Hospital In Ghana A Charles, M v, O Isaac Citation A Charles, M v, O Isaac.. The Internet Journal of Cardiovascular Research Volume 7 Number 1. Abstract The study was carried to establish hypertension as the major cause of heart failure in patients seen at the medicine directorate of a teaching hospital in Kumasi. The study also determined the efficiency of the pharmacotherapeutical management of hypertension in these patients. It was retrospective covering a 3-year period i.e to It involved 307 heart failure patients consisting of 54.7% males and 45.3 females aged between 13 to 100 years with the age range of years forming the majority. The median age of the patients was 54.6 years with a standard deviation of The study was non-randomized and hence all heart failure patients who fell within these periods were used. Hypertension was found to be main cause of heart failure affecting 61.7% (n=189) out of the 307 patients who were admitted for heart failure. The patients had a mean systolic blood pressure of 148.2mmHg (SD.38.49) with the majority (28.7%) having systolic blood pressure in the range of mmHg. Their mean diastolic blood pressure was 92.60mmHg (SD ) with the majority (52.4%) having diastolic blood pressure in the range of mmHg. For asymptomatic heart failure patients with hypertension a thiazide diuretic was found be effective especially for elderly patients over 65 years. 23.8% of the patients in this study received the calcium-channel blocker, nifedipine to treat hypertension in heart failure, however, the newer calcium antagonists, felodipine and amlodipine were more effective in treating arterial hypertension in heart failure. 13.3% of the patients in this study received the β-blocker, carvedilol. Maximizing the dose of β-blockers and ACE-inhibitors, which extend survival in heart failure, was found be more effective than adding calcium-channel blockers to control hypertension. 41.7% of the patients in the study received low dose of the ACE-inhibitor, lisinopril (2.5mg-5mg) to treat symptomatic heart failure due to systolic left ventricular dysfunction, however, maximizing the dosage to 10mg-20mg was found to achieve a decrease in blood pressure as well as improved survival of the patients. The centrally acting drug, methyldopa was administered to 18% of the patients. A dosage of twice daily was found to effectively control their blood pressure. Although most of the patients were discharged with a decreased blood pressure levels the recommended target blood pressure levels of <140/90 or 130/80mmHg could not be achieved. This was due to the fact that most of the patients became asymptomatic and therefore were discharged to be reviewed at the cardiac clinic. INTRODUCTION Hypertension has been associated with an increased risk of heart failure in several epidemiological studies. In the Framingham heart study, hypertension was reported as the cause of heart failure either alone or in association with other factors in over 70% of cases, on the basis on non-invasive assessment(1). Hypertension predisposes to the development of heart failure via a number of pathological mechanisms, including left ventricular hypertrophy. Left ventricular hypertrophy is associated with left ventricular systolic and diastolic dysfunction and an increased risk of myocardial infarction and it predisposes to both atrial and ventricular arrhythmias. Electrocardiographic left ventricular hypertrophy is strongly correlated with the development of heart failure, as it is associated with a 14-fold increase in the risk of heart failure in those aged 65 years or under(16). There have been worrying reports recently both in epidemiology and clinical outcomes of hypertension in recent studies. Hypertension has been reported to account for up to 30% of hospital admissions for heart failure in West Africa(3) and the prognosis of hypertensive heart failure among black Africans has also been found to be poor(4). Amoah and Kallen found the main cause of heart failure in Accra, Ghana to be hypertension(5). Owusu, I., in Kumasi also found the main cause of heart failure to be hypertension(6). Effective management of hypertension in heart failure will decrease stroke by 35-40%, myocardial infarction by 20-25% and congestive heart failure by 50%. The goal of treatment is to reduce cardiovascular and renal morbidity and mortality and vascular dementia by focusing on reducing 1 of 8
2 systolic blood pressure with objective of achieving blood pressure of <140/90 or <130/80 in heart failure patients with diabetes or renal disease(7,8). Aggressive treatment strategies for hypertension in heart failure must begin with prevention, and hypertension represents a major contributing factor. Some have estimated that as many as 90% of persons with heart failure have an antecedent history of hypertension. However, data suggest that only 1/3 of patients have their blood pressure controlled(9). This low control rate is, in part, because of physician and patient behaviours that prevent achievement of blood pressure treatment goals. These behaviours include; Figure 1 Table 1: Oral antihypertensive drugs used in the management of hypertension in heart failure patients. XR = extended release. Adapted from Chobanian AV, Bakris GL. Black HR, Cushman WC, Green, LA, Izzo, Jr. JL, Jones, DW et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003;289: Used with permission. Prescribing suboptimal drug doses or failure to escalate antihypertensive dose Reluctance to prescribe effective drugs due to their side effects Poor patient adherence to prescribed drugs Therefore, to optimally treat heart failure patients with hypertension and achieve target pressure, these barriers must be overcome. Educating patients regarding the risks and consequences of non-adherence, minimizing tolerability issues and side-effects and simplifying dosing regimens may improve adherence to treatment and resulting outcomes. Cochrane review updated in 2004 gives the oral antihypertensive drugs that are used in the management of hypertension in heart failure patients as below; Figure 2 Table 2: Antihypertensive medication and co-morbid conditions In managing hypertension in heart failure, the strategies to adapt are; minimize polypharmacy simplify treatment plan prescribe inexpensive drugs educate patients about disease and goal therapy review medications regularly and discontinue when not needed. 2 of 8
3 MATERIALS AND METHODS Figure 3 STUDY TYPE Table 3: sex distribution of heart failure patients The study was a hospital-based retrospective descriptive carried out at the medicine directorate, Komfo Anokye Teaching Hospital in Kumasi covering a 3-year period from January 2004 to December 2006 involving 307 heart failure patients with hypertension. Figure 4 Figure 1; sex distribution of heart failure patients SAMPLING METHOD Heart failure patients aged between 13 and 100 years who were admitted at the medicine wards of the hospital were non-randomly used. Documentation of patients in the nurses admission and discharge books at the wards was poor and hence only patients who were properly documented within the said periods of the study were used. DATA PROCESSING AND ANALYSIS The data collected using the Data Collection Forms were entered separately into STATA Version 7.0 statistical software for analysis. Descriptive analysis of baseline parameters was provided and numbers and percentages were calculated. LIMITATION OF STUDY As a result of the retrospective nature of the study, some vital information on some patients could not be obtained due to poor documentations in the admission and discharge books at the wards. Some names and folder numbers retrieved from the admission and discharge books could not be traced from the medical records department. These had the potential of affecting the results and might have diluted the observed results. RESULTS 307 patients were involved in the study comprising 168 males and 139 females who were admitted at the medical wards of the medicine directorate from January 2004 to December DEMOGRAPHIC CHARACTERISTICS Sex Distribution Males formed 54.7% whiles females formed 45.3% of the patients in the study. 3 of 8 Age Distribution The ages of the patients admitted with heart failure during the period under review ranged from 13 to 100 years with the range years forming the majority i.e %. The median age of the patients was 54.6 years with a standard deviation (SD) of Figure 5 Table 4; age distribution of heart failure patients
4 Figure 6 Figure 10 Figure 2; age distribution of heart failure patients. Table 8: Mean diastolic blood pressure Figure 11 Figure 3: systolic blood pressure distribution of patients SYSTOLIC BLOOD PRESSURE OF PATIENTS The patients had a mean systolic blood pressure of 148.2mmHg. Figure 7 Figure 12 Table 5: the frequency of the systolic blood pressures of the patients Figure 4: diastolic blood pressure of the patients before treatment Figure 8 Table 6: mean systolic blood pressure DIASTOLIC BLOOD PRESSURE OF PATIENTS Drugs distribution Figure 9 Figure 13 Table 7: Frequency of diastolic blood pressures of the patients. Table 9: drugs used and their frequency 4 of 8
5 Figure 14 Figure 5: pattern of drugs used in managing hypertensive heart failure DISCUSSION The ages of the patients admitted with heart failure during the period under review ranged from 13 to 100 years with the range years forming the majority i.e.16.62%. The median age of the patients was 54.6 years with a standard deviation (SD) of This correlates with the median age of (18.5) reported by Owusu in his study of the causes of heart failure in Kumasi(6). A similar mean age of 53 (12.1) years was reported by Isezuo et al among Gambians and Nigerians with heart failure(4). However, Amoah and Kallen reported a low mean age of 42.3 (0.9) years in their study at the National Cardiothoracic Centre in Accra(5). This may be due to the many congenital heart cases reported at the centre and also being a national referral point, the centre sees a lot of patients of all ages. Males constituted 54.7% and females made up 45.3% of heart failure patients in the study representing a ratio of 1.2:1.0. Amoah and Kallen also reported a similar ratio of 1.2:1.0 of male to female affected with the disease at the National Cardiothoracic Centre in Accra(5). This confirms available data(7,8) that heart failure affects more males than females. This is probably due to the fact that the incidence of hypertension is more prevalent in males than females and hypertension is a major cause of heart failure in the subregion. The main causes of heart failure in this study were hypertension (61.7%). Data available shows that the main cause of heart failure in Africa is hypertension(7,8). This was reported as such by Owusu, in Kumasi(6) and Amoah and Kallen in Accra(5). Given the importance of hypertension, it is alarming that the awareness, treatment, and control rates of hypertension in Africa are as low as 20%, 10% and 1%, respectively(7,8). Owusu reported that the detection and control of hypertension remains a challenge even in developed countries, with as many as 70% of hypertensive patients with uncontrolled high blood 5 of 8 pressure(6). 28.7% of the patients recorded a systolic blood pressure in the range of mmHg whiles the mean systolic pressure recorded was 148.2mmHg. 22.3% of the patients recorded a diastolic blood pressure of 92.6mmHg with as many as 52.4% recording a diastolic blood pressure in the range of mmHg. These results exceeded target blood pressure goals of <140/90 or 130/80mmHg as recommended by guidelines for the management of hypertension in heart failure (9). Physicians are often satisfied with decreasing blood pressure, even if blood pressure target is not achieved. The notion that reaching target diastolic blood pressure goals is satisfactory although systolic blood pressure remains high must be discarded. This is because for patients over 50 years, the systolic blood pressure has been shown to be more important to control than the diastolic blood pressure (10) in managing blood pressure in heart failure patients. TREATMENT Almost all the patients (98.7%) in this study received frusemide, a loop diuretic in accordance with the updated treatment guidelines for heart failure since all the patients were symptomatic. The frusemide was to manage fluid overload and to relieve the patients of symptoms like breathlessness. Strong clinical consensus(19) indicates that diuretics should be used to treat volume overload. A metaanalysis of several small trials also suggests that the use of diuretics reduce the risk of death and worsening heart failure(19). The dose should be carefully tailored to the individual patient to control fluid overload. All the patients had fluid overload either as pulmonary oedema, peripheral oedema or both. For asymptomatic heart failure patients with hypertension the initial recommended medication would have been a thiazide diuretic especially for elderly patients over 65 years. As many as 23.8% of the patients in this study received the calcium-channel blocker, Nifedipine, to treat arterial hypertension in heart failure. However, the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)(15) and a recent meta-analyses(18) suggested that hypertensive heart failure patients treated with calcium-channel blockers are at risk for worsening heart failure. The updated guidelines recommend the use of the newer calcium antagonists i.e. felodipine and amlodipine to treat arterial hypertension in heart failure. 13.3% of the patients in this study received the β-blocker, carvedilol. Owusu, also found that only 17% of heart failure
6 patients in his study received the β-blocker, carvedilol(5). However, maximizing the doses of β-blockers and ACEinhibitors, which extend survival in heart failure, is preferred to adding calcium-channel blockers to control hypertension(16,17). Although 41.7% of the patients in the study received the ACE-inhibitor, lisinopril, dosage was low dose from 2.5mg-5mg to treat symptomatic heart failure due to systolic left ventricular dysfunction, maximizing the dosage to 10mg-20mg would have achieved a decrease in blood pressure as well as improved survival of the patients. A meta-analysis of 32 trials completed before 1995 that involved 7105 patients with heart failure concluded that ACE-inhibitors reduced the total mortality rate by 23% and the combined end point of death from or hospitalization for heart failure by 35%(17). Furthermore, long-term follow-up of these studies suggests that these benefits are sustained over many years. The centrally acting drug methyldopa (i.e. Aldomet) was used in 18% of the patients to treat hypertension. A dosage of twice daily is recommended to lower blood pressure levels. Although most of the patients were discharged with a decreased blood pressure the recommended target blood pressure levels of <140/90 or 130/80mmHg could not be achieved. This was due to the fact that most of the patients became asymptomatic and therefore, were discharged to be reviewed at the cardiac clinic. CONCLUSION Of all the diagnosis made in heart failure, hypertension is the most common cause. However, data suggest that only 1/3 of the patients have their blood pressure controlled. This is mainly due to physicians prescribing suboptimal drug doses or failure to escalate antihypertensive dose. The goal of treatment is to reduce cardiovascular and renal morbidity and mortality and vascular dementia by focusing on reducing systolic blood pressure with goal being <140/90 or <130/80mmHg with hypertensive heart failure with diabetes or renal disease. Initial recommended medication is a thiazide diuretic. After thiazide diuretics, the choice of antihypertensive medications is based on other co-morbid conditions. The newer calcium-channel antagonists, felodipine and amlodipine are recommended to treat hypertension in heart failure. Maximizing the doses of ACEinhibitors and β-blockers will be sufficient to control hypertension in heart failure. Educating physicians and patients regarding the importance of treating to goal is a 6 of 8 crucial step in overcoming barriers that prevent blood pressure goal achievement. Again the simplification of dosing may provide adherence benefits over a twice-or three-time daily drug. Overall, physicians must be confident that aggressive treatment will not result in an adverse benefit-to-ratio for the patient. References 1. Mckee, P.A, Castelli, W.P, McNamera, P.M, Kannel, W.B. (1971). The natural history of heart failure: the Framingham study. N Engl Jmed:285: Cowie, M.R; Mosterd, A; Wood, D. A; Coats, A.J.S; Thompson, S.G. (1997). The Epidemiological features of Heart Failure in developing countries; a review of the literature. Eur Heart J 1997; 18: Toure, L.A; Salissou, O; Chapko, M.K. (1997). Hospitalization in Niger (WA) for complications from arterial hypertension. Afr. J Med. Sci. Dec: 6(4): Isezuo, A. S; Omotoso, A.B.O; Gaye, A; McNamara, P.M. (2000). One year survival among Sub-Saharan Africans with hypertensive heart failure. Tropical Cardiology 2000; 26/no 103: Amoah, A.G; Kallen, C. (2000). Aetiology of heart failure as seen from National Cardiac Referral Centre in Africa; Cardiology 2000;93(1 2): Owusu, I.K. (2007). Causes of Heart Failure As Seen in Kumasi, Ghana. The Internet Journal of Third World Medicine Vol. 5 Number Lapido, G.O; Fronde, J.R; Parry, E.H. (1997). Patterns of heart diseases in adults of the Nigeria Savanna: a prospective clinical study. Afr J Med. Sci 1997 Dec; 6(4): Task Force report. (2001). Guidelines for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J (2001) 22, Copper, R.S; Amoah, A.G; Mensah, G. A. (2003). High Blood Pressure: the foundation for epidermic cardiovascular disease in African populations. Ethn Dis. 2003:13(2 suppl2) Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers; a critical review of the evidence. J Am Coll Cardiol. 2007:50; Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Eng J Med. 1998;339: Izzo JL Jr, Levy D, Black HR. Clinical Advisory Statement: importance of systolic blood pressure in older Americans. Hypertension 2000;35: Hunt, S.A; Baker, D.W; Chin, M.H; Cinquegrani, M.P; Feldman, A.M; Francis, G.S; Namla, J. (2001). ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. 14. Faris, R; Flather, M; Purcell, H; Henein, M; PooleWilson, P; Coats, A.(2002). Current Evidence Supporting the Role of Diuretics in Heart Failure; a meta analysis of randomized controlled trials. Ht J Cardiol. 2002; 82: [PMID: ] 15. Major Outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vrs diuretic (2002). The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). AMA.2002;288: [PMID: ] 16. Lapido, G.O; Fronde, J.R; Parry, E.H. (1997). Patterns of heart diseases in adults of the Nigeria Savanna: a prospective
7 clinical study. Afr J Med. Sci 1997 Dec; 6(4): Task Force report. (2001). Guidelines for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J (2001) 22, Turnbull, F. (2003). Effects of different blood-pressurelowering regimes on major cardiovascular events: results of 7 of 8 protectively- designed overviews of randomized trials. Lancet. 2003;362: [PMID: ] 19. Faris, R; Flather, M; Purcell, H; Henein, M; PooleWilson, P; Coats, A.(2002). Current Evidence Supporting the Role of Diuretics in Heart Failure; a meta analysis of randomized controlled trials. Ht J Cardiol. 2002; 82: [PMID: ]
8 Author Information Anane Charles PhD Cand Clinical Pharmacist, Cardiology and Critical Care, KATH Mensah v Head, Clinical Pharmacy, KATH Owusu Isaac, MD Cardiologist Consultant, KATH 8 of 8
Hypertensive heart failure in Kumasi, Ghana
Open Science Journal of Clinical Medicine 2014; 2(1): 39-43 Published online February 28, 2014 (http://www.openscienceonline.com/journal/osjcm) Hypertensive heart failure in Kumasi, Ghana Isaac Kofi Owusu
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationVolume 2 Number 2 (2011)
Review of Global Medicine and Healthcare Research Volume 2 Number 2 (211) Publisher: DRUNPP Managed by: IOMC Group Website: www.iomcworld.com/rgmhr/ Drug Utilization Pattern and Co-morbidtities Among Hypertensive
More information2017 High Blood Pressure Clinical Practice Guideline
2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationTarget Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD
Target Blood Pressure Attainment in Diabetic Hypertensive Patients: Need for more Diuretics? Waleed M. Sweileh, PhD Associate Professor, Clinical Pharmacology Corresponding author Waleed M. Sweileh, PhD
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationDRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU
Original Article DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU V.Gowri 1, K.Punnagai, K.Vijaybabu 3, Dr.Darling Chellathai 4 1 Assistant Professor
More informationPrescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines
American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,
More informationImproving Medical Statistics and Interpretation of Clinical Trials
Improving Medical Statistics and Interpretation of Clinical Trials 1 ALLHAT Trial & ALLHAT Meta-Analysis Critique Table of Contents ALLHAT Trial Critique- Overview p 2-4 Critique Of The Flawed Meta-Analysis
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationOutcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension
Outcomes and Perspectives of Single-Pill Combination Therapy for the modern management of hypertension Prof. Massimo Volpe, MD, FAHA, FESC, Chair of Cardiology, Department of Clinical and Molecular Medicine
More informationHypertension Update. Aaron J. Friedberg, MD
Hypertension Update Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Background Diagnosis Management Overview Guideline
More informationInternational Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.8, No.8, pp , 2015
International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: 0974-4304 Vol.8, No.8, pp 131-135, 2015 Assessment of Hypertension ledge Among Pharmacists in Medan City, North Sumatera Khairunnisa*,
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationOriginal article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital
Original article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital Pyarelal Associate Professor, Department of Pharmacology, Mediciti Institute of Medical
More informationStudy of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri
Original Research Article Study of rhythm disturbances in acute myocardial infarction in Government Dharmapuri Medical College Hospital, Dharmapuri P. Sasikumar * Department of General Medicine, Govt.
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationHYPERTENSION IN ME EUIERLY HYPERTENSION AM) CARDIOVASCULAR RISK VALUE OF TREATMENT
HYPERTENSION IN ME EUIERLY K. O'Malley, M. S. Laher, E. T. O'Brien Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, and Hypertension Evaluation and Treatment Clinic, The Charitable
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationShould beta blockers remain first-line drugs for hypertension?
1 de 6 03/11/2008 13:23 Should beta blockers remain first-line drugs for hypertension? Maros Elsik, Cardiologist, Department of Epidemiology and Preventive Medicine, Monash University and The Alfred Hospital,
More information1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril.
SUMMARY 1. Despite the plethora of new ACE-inhibitors they offer little advantage over the earlier products captopril and enalapril. 2. While diuretics and beta-blockers remain first-line antihypertensive
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationLarge therapeutic studies in elderly patients with hypertension
(2002) 16 (Suppl 1), S38 S43 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh Large therapeutic studies in elderly patients with hypertension Centro Clinico Profesional
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationPreventing the cardiovascular complications of hypertension
European Heart Journal Supplements (2004) 6 (Supplement H), H37 H42 Preventing the cardiovascular complications of hypertension Peter Trenkwalder* Department of Internal Medicine, Starnberg Hospital, Ludwig
More information5.2 Key priorities for implementation
5.2 Key priorities for implementation From the full set of recommendations, the GDG selected ten key priorities for implementation. The criteria used for selecting these recommendations are listed in detail
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationReceived: / Revised: / Accepted: / Published:
World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original
More informationIncidental Findings; Management of patients presenting with high BP. Phil Swales
Incidental Findings; Management of patients presenting with high BP Phil Swales Consultant Physician Acute & General Medicine University Hospitals of Leicester NHS Trust Objectives The approach to an incidental
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationHypertension Update 2009
Hypertension Update 2009 New Drugs, New Goals, New Approaches, New Lessons from Clinical Trials Timothy C Fagan, MD, FACP Professor Emeritus University of Arizona New Drugs Direct Renin Inhibitors Endothelin
More informationTouyz, R. M., and Dominiczak, A. F. (2016) Hypertension guidelines: is it time to reappraise blood pressure thresholds and targets? Hypertension, 67(4), pp. 688-689. There may be differences between this
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationPharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014
Pharmacological Treatment for Chronic Heart Failure Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014 1 ACC/AHA 2005 guideline update for Diagnosis & management of CHF in the Adult -SA Hunt
More informationHypertension Clinical case scenarios for primary care
Hypertension Clinical case scenarios for primary care Implementing NICE guidance August 2011 NICE clinical guideline 127 What this presentation covers Five clinical case scenarios, including: presentation
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationCauses of Poor BP control Rates
Goals Of Hypertension Management in Clinical Practice World Hypertension League (WHL) Meeting Adel E. Berbari, MD, FAHA, FACP Professor of Medicine and Physiology Head, Division of Hypertension and Vascular
More informationDr. A. Manjula, No. 7, Doctors Quarters, JLB Road, Next to Shree Guru Residency, Mysore, Karnataka, INDIA.
Original Article In hypertensive patients measurement of left ventricular mass index by echocardiography and its correlation with current electrocardiographic criteria for the diagnosis of left ventricular
More informationExecutive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1
IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationTreatment to reduce cardiovascular risk: multifactorial management
Treatment to reduce cardiovascular risk: multifactorial management Matteo Anselmino, MD PhD Assistant Professor San Giovanni Battista Hospital Division of Cardiology, Department of Internal Medicine University
More informationLISINOPRIL PLUS HYDRO- CHLOROTHIAZIDE IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION: AN OPENED, MULTI- CENTRE, PROSPECTIVE CLINICAL TRIAL
&FIXED COMBINATION LISINOPRIL PLUS HYDRO- CHLOROTHIAZIDE IN THE TREATMENT OF ESSENTIAL ARTERIAL HYPERTENSION: AN OPENED, MULTI- CENTRE, PROSPECTIVE CLINICAL TRIAL Vjekoslav Gerc¹, Begler Begović²*, Midhat
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationSummary of recommendations
Summary of recommendations Measuring blood pressure (BP) Use the recommended technique at every BP reading to ensure accurate measurements and avoid common errs. Pay particular attention to the following:
More informationORIGINAL INVESTIGATION. Calcium Antagonists and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study
ORIGINAL INVESTIGATION s and Mortality Risk in Men and Women With Hypertension in the Framingham Heart Study Vivian M. Abascal, MD; Martin G. Larson, ScD; Jane C. Evans, MPH; Ana T. Blohm, BA; Kim Poli,
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationThe Evolution To Treatment Of Hypertension With Advanced Formulation
The Evolution To Treatment Of Hypertension With Advanced Formulation Dr. Donald Ang MBChB (UK) FRCP (Edin) MD (UK) CCST Cardiology (UK) FESC (Europe) Consultant Cardiologist Island Hospital Penang High
More informationCardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management
Cardiovascular Guideline-Driven Pharmacotherapies: Optimizing Management David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management
More informationAbbreviations Cardiology I
Cardiology I and Clinical Controversies Joseph J. Saseen, Pharm.D., FCCP, BCPS (AQ Cardiology) Reviewed by Stuart T. Haines, Pharm.D., FCCP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning
More informationWhich antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017
Which antihypertensives are more effective in reducing diastolic hypertension versus systolic hypertension? May 24, 2017 The most important reason for treating hypertension in primary care is to prevent
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationHealthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationState of the art treatment of hypertension: established and new drugs. Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland
State of the art treatment of hypertension: established and new drugs Prof. M. Burnier Service of Nephrology and Hypertension Lausanne, Switzerland First line therapies in hypertension ACE inhibitors AT
More informationLowering blood pressure in 2003
UPDATE CLINICAL UPDATE Lowering blood pressure in 2003 John P Chalmers and Leonard F Arnolda Institute for International Health, University of Sydney, Sydney, NSW. John P Chalmers, MD, FRACP, Professor
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationMetabolic Consequences of Anti Hypertensives: Is It Clinically Important?
Metabolic Consequences of Anti Hypertensives: Is It Clinically Important?,FACA,FICA,MASH,FVBWG,MISCP CONSULTANT OF CARDIOLOGY DIRECTOR OF PORT-FOUAD HOSPITAL CCU Consideration of antihypertensive agents
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationREDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT
REDUCING COSTS AND IMPROVING HYPERTENSION MANAGEMENT Vida Stankus 1, Brenda Hemmelgarn 2, Norm RC Campbell 2, Guanmin Chen 2, Finlay A McAlister 1, Ross T Tsuyuki 1 1 EPICORE Centre, Department of Medicine,
More informationΥπέρταση στις γυναίκες
Υπέρταση στις γυναίκες Ελένη Τριανταφυλλίδη Διευθύντρια ΕΣΥ Καρδιολογίας Υπεύθυνη Αντιυπερτασικού Ιατρείου Β Πανεπιστημιακή Καρδιολογική Κλινική Νοσοκομείο ΑΤΤΙΚΟΝ Cardiovascular disease is the Europe
More information47 Hypertension in Elderly
47 Hypertension in Elderly YOU DO NOT HEAL OLD AGE; YOU PROTECT IT; YOU PROMOTE IT; YOU EXTEND IT Sir James Sterling Ross Abstract: The prevalence of hypertension rises with age and the complications secondary
More informationAdherence to International Guidelines in the Management of Hypertension in a Tertiary Hospital in Nigeria
Tropical Journal of Pharmaceutical Research, June 2008; 7 (2): 945-952 Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria. All rights reserved. Research Article Available
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationThe prevalence of hypertension in a representative
CLINICAL STRATEGIES FOR OPTIMAL HYPERTENSION MANAGEMENT Roger S. Blumenthal, MD * ABSTRACT In the United States, approximately 25% of the adult population older than 40 years has hypertension. Americans
More informationHow Low Do We Go? Update on Hypertension
How Low Do We Go? Update on Beth L. Abramson, MD, FRCPC, FACC As presented at the University of Toronto s Saturday at the University Session (September 2003) Arecent World Health Organization report states
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationNurse-sensitive factors in hypertension management
Nurse-sensitive factors in hypertension management Hypertension treatment State of the Art Copper Hall 14:45-15:04 02/04/2011 Philippe van de Borne, MD, PhD Department of cardiology ULB-Erasme Hospital
More informationA fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension: Results of a noninvestigational
Hostalek U et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 11 RESEARCH ARTICLE A fixed-dose combination of bisoprolol and amlodipine in daily practice treatment of hypertension:
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationPrevalence of left ventricular hypertrophy in a hypertensive population
European Heart Journal (1996) 17, 143-149 Prevalence of left ventricular hypertrophy in a hypertensive population J. Tingleff, M. Munch, T. J. Jakobsen, C. Torp-Pedersen, M. E. Olsen, K. H. Jensen, T.
More informationDRUG UTILIZATION EVALUATION OF ANTI-HYPERTENSIVE AGENTS IN A MEDICAL CARE HOSPITAL
Eslampanah, IJPSR, 20; Vol. 7(2): 82-87. E-ISSN: 0975-82; P-ISSN: 20-548 IJPSR (20), Vol. 7, Issue 2 (Research Article) Received on August, 205; received in revised form, November, 205; accepted, January,
More informationTreatment of Heart Failure: Current Recommendation Waiz A
Treatment of Heart Failure: Current Recommendation Waiz A The impaired left ventricular emptying that characterizes heart failure may result from a variety of cardiac diseases, including myocardial ischaemia
More information